Research programme: cyclo-oxygenase-2 inhibitors - Nobex

Drug Profile

Research programme: cyclo-oxygenase-2 inhibitors - Nobex

Alternative Names: COX-2 inhibitors research programme - Nobex; Cyclo-oxygenase-2 inhibitors research programme - Nobex; NNB 001; NNB 004; NNB 005; Research programme: COX-2 inhibitors - Nobex

Latest Information Update: 31 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nobex Corporation
  • Class
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 31 Mar 2004 Discontinued - Preclinical for Rheumatic disorders in USA (PO)
  • 24 Jan 2001 New profile
  • 24 Jan 2001 Nobex's COX-2 inhibitors programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top